WO1994024181A1 - Encrustation and bacterial resistant coatings for medical applications - Google Patents
Encrustation and bacterial resistant coatings for medical applications Download PDFInfo
- Publication number
- WO1994024181A1 WO1994024181A1 PCT/US1994/004107 US9404107W WO9424181A1 WO 1994024181 A1 WO1994024181 A1 WO 1994024181A1 US 9404107 W US9404107 W US 9404107W WO 9424181 A1 WO9424181 A1 WO 9424181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coating
- acid
- hypol
- aminopolycarboxylic acid
- catheter
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 59
- 230000001580 bacterial effect Effects 0.000 title abstract description 31
- 239000011248 coating agent Substances 0.000 claims abstract description 44
- 239000002253 acid Substances 0.000 claims abstract description 18
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 17
- 239000002601 urease inhibitor Substances 0.000 claims abstract description 11
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims abstract description 6
- 229940090496 Urease inhibitor Drugs 0.000 claims abstract description 6
- 239000007795 chemical reaction product Substances 0.000 claims abstract 3
- 229920001778 nylon Polymers 0.000 claims description 48
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 39
- 229960001484 edetic acid Drugs 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 230000000844 anti-bacterial effect Effects 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 19
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical group ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 16
- 230000002485 urinary effect Effects 0.000 claims description 16
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 13
- 239000007822 coupling agent Substances 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- MJPXFHUUIAIRSC-UHFFFAOYSA-N acetic acid;1,1-diaminopropan-1-ol Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCC(N)(N)O MJPXFHUUIAIRSC-UHFFFAOYSA-N 0.000 claims description 3
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- ZRCDAETWRHSWPW-UHFFFAOYSA-N 1,1-diaminopropan-1-ol;2-hydroxyacetic acid Chemical compound OCC(O)=O.CCC(N)(N)O ZRCDAETWRHSWPW-UHFFFAOYSA-N 0.000 claims 1
- 150000002989 phenols Chemical group 0.000 claims 1
- 239000004677 Nylon Substances 0.000 description 46
- 239000000243 solution Substances 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 108010046334 Urease Proteins 0.000 description 32
- 210000002700 urine Anatomy 0.000 description 29
- 108010040201 Polymyxins Proteins 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 229920001296 polysiloxane Polymers 0.000 description 17
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 230000010065 bacterial adhesion Effects 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 229920002302 Nylon 6,6 Polymers 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 10
- 239000004809 Teflon Substances 0.000 description 9
- 229920006362 Teflon® Polymers 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 229920002635 polyurethane Polymers 0.000 description 8
- 239000004814 polyurethane Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- ZZPKZRHERLGEKA-UHFFFAOYSA-N resorcinol monoacetate Chemical compound CC(=O)OC1=CC=CC(O)=C1 ZZPKZRHERLGEKA-UHFFFAOYSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000004816 latex Substances 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- -1 Ag+ ions Chemical class 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229920000557 Nafion® Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960005131 nitroxoline Drugs 0.000 description 5
- 239000003973 paint Substances 0.000 description 5
- 150000007660 quinolones Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000019206 urinary tract infection Diseases 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 244000110797 Polygonum persicaria Species 0.000 description 4
- 108010093965 Polymyxin B Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229940041153 polymyxins Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052567 struvite Inorganic materials 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 201000007717 corneal ulcer Diseases 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 229960003548 polymyxin b sulfate Drugs 0.000 description 3
- 229910001923 silver oxide Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- ZCSWOYDEEZMOMR-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(C)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 ZCSWOYDEEZMOMR-UHFFFAOYSA-N 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010051998 Febrile infection Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- UOBBIPAUPQMONE-UHFFFAOYSA-N magnesium;2-hydroxypropane-1,2,3-tricarboxylic acid;oxygen(2-) Chemical compound [O-2].[Mg+2].OC(=O)CC(O)(C(O)=O)CC(O)=O UOBBIPAUPQMONE-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005289 physical deposition Methods 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 108010019783 tear proteins Proteins 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/0804—Manufacture of polymers containing ionic or ionogenic groups
- C08G18/0819—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups
- C08G18/0823—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups containing carboxylate salt groups or groups forming them
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31551—Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
Definitions
- This invention relates to medical devices that are resistant to bacterial growth or encrustation such as a) urinary catheters and more particularly to urinary catheters constructed of a material which enables the urinary catheters to inhibit urease and to prevent calcium and magnesium phosphate deposits on the catheters and b) contact lenses, more particularly to extended wear lenses coated with a suitable material to enable the lenses to resist the adherence of microorganisms.
- urinary Catheters Catheters are used in urological surgery and when other methods of managing urinary- incontinence fail. These catheters are generally made from a non-toxic, non-irritating material which is flexible but which will withstand collapse. Ideally they should resist colonization by bacteria and encrustation by mineral deposits.
- Urease catalyzes the hydrolysis of urea at an enormous rate (l ⁇ l times as fast as the spontaneous hydrolysis of urea which is not observable in neutral solution) producing ammonia, which in turn precipitates calcium phosphates.
- Microbial heterogeneity and structural complexity of the bio-films observed on infected catheter materials by means of scanning and transmission electron microscopy reveal a variety of microflora. It appears that the adherent microcolonies of bacteria are much less susceptible than their planktonic counterparts to antibiotics because the extensive anionic matrix surrounding the cell appears to comprise an ion exchange barrier between charged antibiotic molecules and their cellular targets. Antibiotics should be reserved for symptomatic, febrile infections; otherwise their use produces a change in bacterial flora with the potential for producing resistance.
- Bacteriurea in a catheterized patient indicates the urinary tract has become colonized or infected.
- Administration of anti-bacterials such as nitrofurantoin, methenamine, and naldixic acid are used in practice. Most of these are not very effective in alkaline urine, and to achieve a high concentration in urine, the patient has to be given enormous doses.
- Catheter associated bacteriurea results from ascending bacterial colonization within glycocalyx enclosed biofilm on the inside and/or outside surfaces of the catheter and drainage systems.
- Urinary tract catheters made from a biomaterial that inhibits bacterial adherence and thus retards upstream colonization of bacteria may reduce acquired urinary tract infection (UTI) . While hydrophilic surfaces show reduced protein adhesion, antibacterial surfaces offer better protection. Either a controlled release or an antibacterial immobilized on the surface should offer continuous protection against bacterial colonization.
- UTI urinary tract infection
- hydrophilic surfaces show reduced protein adhesion, antibacterial surfaces offer better protection. Either a controlled release or an antibacterial immobilized on the surface should offer continuous protection against bacterial colonization.
- a silver oxide catheter is described in a publication by Shaeffer, A.J., Story, K.O., Johnson, S.M.
- the antimicrobial agent is simply mixed with the ethylene/vinyl acetate polymer during the fabrication of the funnel.
- the catheter surface itself does not carry any antimicrobial nor is it capable of preventing encrustation.
- U.S. Patent 4,579,554 issued to Jacob Glassman discloses a design that provides for irrigation of the catheter tube. Frequent irrigation, however, could result in the damage of the mucus in the bladder.
- U.S. Patent 4,642,104 issued to Sakamoto et al. teaches the use of polymers carrying multicarboxyl, amino or sulfonic acid group capable of binding antibiotics through ion exchange.
- the ion exchange groups are chemically introduced into the molecules of the inside and outside wall of the urethral catheter by hydrolysis of certain functionalities that are present in the polymer that is coated on the surface of the catheter.
- Cationic antibiotics such as polymyxins or soap preparations such as benzalkonium chloride or benzethionium chloride, cyclohexidine or povidine-iodine remain on the surface due to the electrostatic binding.
- U.S. Patent 4,950,256 issued to Luther et al. teaches the use of an intravascular catheter comprising a cannula for insertion into a vascular system of a patient.
- This catheter is coated with a hydrophilic polyurethane-polyene composition for binding antithrombogenic materials and cationic polymyxin antibiotics .
- Luther et al . show that the absorption of the polymyxins into the hydrophilic polyurethane can be controlled by varying the initial concentrations . The authors describe this as a time release intravascular catheter.
- the present invention differs from that of Luther et al. , by virtue of the immobilization of polymyxin through a binding action with the dianionic diaminopropanol tetraacetic acid (DPTA) groups.
- DPTA diaminopropanol tetraacetic acid
- Infective ulcerative keratitis is one of the most severe hazards of hydrogel extended wear soft contact lenses (SCLs) .
- SCLs hydrogel extended wear soft contact lenses
- the extent of bacterial adherence varies with the nature of the base materials, protein deposits and surface charges. While the mechanism of adhesion and colonization of bacteria on SCLs is not well understood, the influence of adsorbed proteins has been implicated. Recently it was reported ("Pseudomonas attachment to low-water and high-water and non-ionic, new and rabbit worn soft contact lenses," Brussel et al., Investigative Ophthalmology and Visual Science, 32, 657, 1991) that both new and worn SCLs can bind amounts of P. aeruginosa that could potentially produce bacterial keratitis.
- SCLs in the eye are readily coated with tear proteins, mucus and lipids (Tripathy et al. , "Lens Spoilage in Contact Lenses, " in The CLAO guide to basic and applied clinical practice, " Dabecies O.H. Jr. (Ed), Grune and Stratton Inc., Orlando Fl, 1984) .
- P. aeruginosa is the responsible microorganism in up to two thirds of the reported cases of extended wear SCL associated infectious keratitis .
- the extended wear contact lens induces corneal hypoxia, microtrauma and tear film destruction that weaken corneal defense.
- Another object of the present invention is to provide a catheter for use in urological surgery or for managing urinary incontinence which causes a lower risk of infection than known catheters.
- Urinary catheters of the present invention are made of materials that a) prevent the adherence of bacteria, b) inhibit urease, and c) prevent calcium and magnesium phosphate deposits on the material. Such urinary catheters are especially useful when intended for use for extended periods.
- the invention includes the surface modification of, high surface area carbon by means of a reactive hydrophilic polymer which forms a composite when painted on a braided nylon. The carbon modified polymer paint can be coated on all plastic materials including latex.
- the coated catheter remains flexible and hydrophilic and allows equilibration of ions and offers a reactive surface.
- This invention has been extended to apply to contact lenses.
- Lenses coated with carbon-free formulations of the present invention show excellent resistance to P. aeruginosa .
- Certain chemical modification schemes of the surface of the contact lens were also successful.
- the present invention differs from the prior art in several ways: 1) it uses antibacterials that could covalently bind to the -NCO group of a prepolymer such that the antibacterial would become a part of a hydrophilic polyurethane backbone of the coating, 2) it uses an oxidized high area carbon which is extremely effective in binding Ag + ions and antibacterials such as polymyxin through its carboxylic groups .
- the C00 ⁇ groups can also bind cationic ingredients such as aminopolycarboxylic acids and their derivatives capable of chelating Ca 2+ and Mg2+ coupled with Ag + which is a urease inhibitor along with antibacterials such as fluoroquinolones, quinolones and other antibacterials make the coating of the present invention a triple defense system. 3) It uses cyanuric chloride (trichloro-s-triazine) as a coupling agent to react with hydroxyl groups on surfaces.
- cyanuric chloride trichloro-s-triazine
- Fig. 1 is a sectional view of the coating configuration of the present invention.
- Fig. 2 is a perspective view of apparatus used to study the encrustation of urinary catheter samples coated in accordance with the present invention.
- Fig. 3 is a graph showing encrustation weight per unit area, for the Urease Encrustation Model in which the Y-axis on the left shows weight rationalized on the basis of geometric area and Y-axis on the right shows the data for real surface area.
- Fig. 4 is a graph showing encrustation weight per unit area, for the Bacterial Encrustation Model in which the Y-axis on the left shows weight rationalized on the basis of geometric area and Y-axis on the right shows the data for real surface area.
- Fig. 5 is a plot of bacterial adhesion data for P. Mirabalis for all samples including the silicone and Teflon controls.
- Fig. 6 is a plot of bacterial adhesion data for P. Mirabalis for the samples from the present invention only.
- Fig. 7 is a plot of bacterial adhesion data for P. Vulgari ⁇ for all samples including the silicone and Teflon controls.
- Fig. 8 is a plot of bacterial adhesion data for P. Vulgaris for selected samples along with the controls.
- Fig. 9 is a graph showing the effect of different treatments on the bacterial adhesion on IV catheter materials.
- Fig. 10a is a perspective view of a contact lens.
- Fig. 10b is a cross sectional view of the lens shown in Fig. 10a.
- Fig. 10c is an expanded schematic of the covalent coupling of diaminopropanoltetra acetic acid to the lens surface through a bridge of cyanuric chloride.
- Fig. lOd is also a cross sectional view of the contact lens of the type shown in Fig. 10a.
- Fig. lOe shows an enlarged view of a thin coating of Hypol R /Polyox ⁇ coating as explained in Example 10.
- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following is a detailed description of two embodiments of the present invention:
- the coating for catheters of the present invention that minimizes encrustation and/or infection, as encountered in known urinary catheters includes a coating having a hydrophilic polyurethane pre ⁇ polymer, a high area filler which is preferably carbon (but silica or alumina and other agents may be used which chelate calcium and magnesium in the body fluids that cause encrustation) , anti-bacterial agents such as quinolones and urease inhibiting agents such as silver ions and EDTA.
- Aminopolycarboxylic acids such as ethylene diamine tetraacetic acid, and iminodiacetic acid are powerful chelating agents for Ca and Mg at pH's between 8-10.
- ethylene diamine tetraacetic acid exists mostly in the form of H2 Y 2 ⁇ (Y 4 - is the tetra ion) and small amounts of Y 4- , H3 Y ⁇ and H4 Y.
- the concentration of Y 4_ is 40% of the total concentration of the ethylene diamine tetraacetic acid.
- quinolones are currently undergoing more innovation, and the interest far exceeds that in the cefalosporins and aminoglycosides.
- the quinolones are bactericidal and the minimum inhibitory concentration, in general, increases in presence of divalent cations due to their tendency to form complexes.
- the use of resorcinol or resorcinol monoacetate antiseptic agent has already been established for external uses. Incorporation of resorcinol monoacetate in collagen based biomaterials show dramatic evidence of bacterial inhibition even at a 2% w/w concentration. When this functionality is bonded to the catheter surface, one might expect to see long-term antibacterial effects.
- Hypol R a hydrophilic polyurethane prepolymer sold by W.R. Grace under the trade name Hypol R .
- Hypol 5000 a pale yellow, high viscosity liquid which is a MDI based prepolymer that contains 2.55 meq/g of free -NCO group and its various reactions with -OH and -COOH groups are shown below.
- IR spectral data indicates the absence of -NCO groups and the presence of urethane, -COOH and -OH groups in the cured sample.
- High area carbon can be used as an excellent support material for polymers such as Hypol. Diluted Hypol after chemical coupling with the appropriate compound blends very well with hydrophilic Cabot M-1300 carbon and forms a paint ⁇ like formulation.
- the surface area measurements of carbon loaded with Hypol tubings after complete cure showed an area of 3000 cm 2 /g.
- the surface area of a silicone tube used as control in the experiments was only 270 cm ⁇ /g.
- Hypol also proved to be an excellent binder for carbon and during all incubation studies of the various Hypol/Carbon catheter materials, microscopic carbon particles were not detected.
- the high surface area of the carbon (>50 sq.m/g) coupled with its ability to provide reactive surface groups for the attachment of various ligands would facilitate a high surface concentration of the ligand moieties.
- the urease concentration on the surface will be of micromole quantities .
- the aminopolycarboxylic ligands are capable of reversibly binding Ca 2+ or Mg 2+ depending upon the pH.
- the high surface concentrations of powerful urease inhibitors, such as Ag + along with antibacterials are expected to provide a powerful barrier against infecting bacteria and urease.
- the equilibration between the surface and the urine must be rapid due to the expansion of the hydrogel or ionomer coatings allowing diffusion of various species .
- Nylon 6,6 fibers are used as support for the Hypol- carbon coatings; this support material allows the construction of tubings with different formulations and serves as a basis for proving the feasibility of this approach.
- the coated tubes can themselves be used as collapsible catheter material, although, several other designs are possible.
- An Ag-nylon material has also shown excellent adhesion to Hypol-carbon paint compared to plain nylon 6,6. The results also show better microbial protection when Ag-nylon is used in combination with ethylene diamine tetraacetic acid.
- the nylon/Hypol R tubing were quite rigid, and would not collapse under normal usage.
- the coating configuration is shown in Figure l as a longitudinal cross section of a portion of the catheter tube 10.
- the cross-hatched portion 11 is the nylon weave which is braided onto a plastic core (not shown) . This core is removed after the coating process to obtain the catheter tube 12.
- the granular material 14 shown in Fig. 1 in the nylon braid 15 represents the carbon black.
- the nylon braid 15 is completely covered with the Hypol/carbon paint 16. All the coatings were moisture cured overnight at room temperature and the coated tubes were stored at room temperature.
- incorporation implies special methods of covalent attachment of the reagents on high surface area carbon followed by hydrogel encapsulation of carbon. Active carbon has been successfully encapsulated and has been used in the removal of toxins from blood.
- the hydrogel coatings reinforced with carbon and nylon fibers show superior mechanical strength compared to pure hydrogel coatings.
- Infective ulcerative keratitis is one of the most severe hazards of hydrogel extended wear soft contact lenses . Three new approaches are presented here to overcome this problem.
- the first approach is based on the reactivity of trichloro-s-triazine (cyanuric chloride) toward -OH groups on the soft contact lens material surface.
- Cyanuric chloride (CC) as a coupling agent has been used in certain controlled delivery systems and has been proven to be safe (Petrak, K. , 'Pharmaceutical Applications of Functionalized Polymers', in Reactive Polymers, vol. 10, page 231, 1989) . Even though cyanuric chloride is toxic due to the active chlorine, once the chlorides are coupled to IDA or EDTA moieties, the resulting structure is inert and non-toxic. The resulting ether linkages are inert to hydrolysis.
- FIG. 10a shows a side view of the surface modified contact lens.
- Fig. 10b is a cross sectional view of the lens.
- Fig. 10c shows an enlarged view of the binding of the DPTA or IDA to the lens surface through cyanuric chloride bridge.
- Such treatments and covalent linking can also be achieved using cyanogen bromide or cyanogen chloride as the coupling agent.
- Covalently bound chelating agents like DPTA could still bind Ca 2"1" and disrupt the cell wall of the bacteria. The same chelating effect is expected of iminodiacetic acid which readily bonds to CC.
- bactericidal agents functioning by their cation complexing action upon the cell wall do not need to be incorporated into the bacterial cell to be effective as bactericides.
- a water soluble antibiotic such as polymyxin sulfate B (a large cation) can be bound to the C00 ⁇ rich surface. (This antibiotic is presently used as a topical medication for contact lens related infections) .
- Polymyxins are one among the very few antibiotics which are known to inhibit P. aeruginosa .
- the group of polymyxin includes closely related circulins and colistins . These are closely related to cyclic lipopeptides. They are branched cyclo- octa, deca or undeca peptides that are monoacetylated in the aminoacyl side chains with branched chain fatty or B-hydroxy fatty acids.
- These antibiotics are characterized by a high percentage of a, r- diaminobutyric acid, the presence of several aminoacids and a heptapeptide ring and by the fatty acid attachment to the N-terminal of the peptide side chain through an amide bond.
- the polymyxins are deca-peptides containing Cg or C9 fatty acids.
- the second approach is based on the discovery that polymyxin sulfate B is capable of adsorbin on the polyhema surface of the contact lens.
- polymyxin sulfate B is capable of adsorbin on the polyhema surface of the contact lens.
- polymyxin B sulfate in contact with the surface of the Surevue lenses was irreversibly bound. This discovery is further explained in Example 11, where it is shown that after treatment with polymyxin B sulfate, and several rinses of the lens, no bacterial adhesion is found.
- polymyxin B is extracted by poly- hema contact lens and retained after several washings can be explained on the basis of solubilities of various lipophilic drugs in p.hema.
- Drugs such as chloramphenicol, pilocarpine, dexamethasone etc., were found to have a longer washout period when entrapped in intraocular lenses (T.P. Heyrman, M.L. McDermott, J.E. Ubels and H.F. Edelhauser, in Journal of Cataract Refractory Surgery, vol 15, page 169, 1989) .
- Gentamicin soaked contact lenses made of 61.4% p.hema hydrogel were found to retain bactericidal concentrations of the antibiotic for three days of eye contact (M. Busin, M. Spitznes, Ophthalmology, vol 95, page 796, 1988) . Ionic binding of cationic polymyxin by the anionic carboxyl groups is also possible.
- an optically clear, adherent coating can be obtained using Hypol R in combination with small amounts of polyethylene oxide with or without antibacterials.
- a schematic illustration of such a coating is shown in Fig. lOd, with Fig. lOe showing an enlarged view of the coating on the lens surface.
- the cured coatings incorporate, by covalent bonding, the organic functionalities in the polyurethane backbone.
- the pre ⁇ polymer polyurethane forms a clear, highly adherent, hydrophilic coating on the soft contact lenses.
- Hypol 5000 a hydrophilic polyurethane prepolymer, MDI based, 2.5 meq. NCO per gram, W.R. Grace
- Hypol 5000 a hydrophilic polyurethane prepolymer, MDI based, 2.5 meq. NCO per gram, W.R. Grace
- 5 mmoles each of ethylene diamine tetraacetic acid, iminodiacetic acid, resorcinol monoacetate, and nitroxolin were added, and stirred well.
- dry methylene chlo ⁇ ride 70 ml
- Pluronic L-101 a few drops of a surfactant, Pluronic L-101.
- the mixture was homogenized with a homogenizer or sonicator and used for coating after the addition of dry carbon (Carbon black, M-1300, Cabot Co., 7 g) .
- Desired consistency is obtained by the addition of more solvent. All formulations hardened within 2-4 hrs.
- Synthetic urine was prepared as described in Griffith, D.P., Musher, D.M., and Itin, C, "Urease -- The Primary Cause of Infection Induced Urinary Stones, " Investigative Urology, 13, 346 (1974) with the following composition (Table I) .
- the apparatus 22 used is shown in Fig. 2.
- Artificial urine was added into an experimental vessel 24 (where the catheter tubes 26 were suspended) .
- the vessel should have an inlet 28 and an overflow outlet 30.
- a vent 32 is also provided.
- the experimental vessel 24 was gently stirred o with magnetic stirrer 34 while incubating at 37 C.
- the urease addition test model resulted in variable encrustation of all samples in Figure 3.
- the surface density of the encrustation were calculated based on the geometric area exposed to the synthetic urine.
- the results clearly show that the ethylene diamine tetraacetic acid modified surface has low encrustation.
- the results are even more dramatic if the real surface areas are used for calculating the surface density; the best samples constructed in accordance with the present invention show almost an order of magnitude less encrustation than silicone tubing. Visual inspection of the samples showed chunky white deposit on the silicone tube, whereas only a white powdery layer on the samples constructed in accordance with the present invention.
- the extent of encrustation is clearly related to the presence of antibacterials, chelating agents and urease inhibitors . An optimum combination of the three could prove better than just one defense mechanism. The extent of encrustation should also be dependent on the surface concentrations of the three classes of compounds. It must be emphasized that the test catheter tubes contained only 0.5 mmoles/g of Hypol in the coating; only two coatings (4 mil total) of this material was loaded on the nylon support.
- a dynamic perfusion model was used.
- the apparatus 22 used in this example is shown in Fig. 2.
- Artificial urine was allowed to flow into an experimental vessel 24 (where the catheter tubes 26 were suspended) at a controlled rate (1.2 L/day) .
- the vessel should have an inlet 28 and an overflow outlet 30.
- a vent 32 is also provided.
- Proteus mirabalis was cultured in Trypticase soy broth/urea agar medium by using a cultiloop (BBL labs) .
- the experimental setup was inoculated with enough bacterial broth to give a turbidity of McFarlane #1 and was checked for bacterial count of lXlO ⁇ /mL.
- the experimental vessel 24 was gently stirred with magnetic o stirrer 34 while incubating at 37 C. Bacterial counts were checked everyday in the outflowing liquid.
- the bacterial encrustation model results shown in Fig. 4 indicate that antibacterial agents lower the encrustation more efficiently than chelating agents and urease inhibitors.
- the bacterial encrustation along with the urease inhibition study indicate relatively low amounts of encrustation for surfaces modified by ethylene diamine tetraacetic acid. It appears that Hypol bound ethylene diamine tetraacetic acid still maintains its chelating ability. In addition, the large surface area of the carbon loaded polymer coating appears to allow physical deposition of hydroxyapatite rapidly as the pH rises resulting in a powdery precipitate. The solubilizing action of ethylene diamine tetraacetic acid helps loosen the deposit. It appears that the antibacterial properties of ethylene diamine tetraacetic acid coupled with its ability to chelate Ca + could be advantageously used for catheter coatings .
- ethylene diamine tetraacetic acid modified surface is that at pH values below 8, protons compete very efficiently with Ca 2+ ions, thus regenerating the surface enriched with uncomplexed ethylene diamine tetraacetic acid.
- protons compete very efficiently with Ca 2+ ions, thus regenerating the surface enriched with uncomplexed ethylene diamine tetraacetic acid.
- ethylene diamine tetraacetic acid complexes nickel centers from urease and thus becomes an urease inhibitor.
- Ca + and Mg + occurs with the release of protons . Therefore in the final form the catheters could revive their surface if the patient's urine becomes slightly acidic. Since the inner surface of the catheter is more prone to encrustation, it is possible to incorporate ethylene diamine tetraacetic acid on the inner surface essentially by the same methods .
- the outer surface of the catheter could contain simply antibacterials or lower surface concentration of ethylene diamine tetraacetic acid. These tubes can even be used as inner inserts for regular Foley catheters with appropriate redesign.
- EXAMPLE 8 Cultures and cultural conditions: Two bacterial strains, Proteus mirabilis and Proteus vulgaris, were used in these experiments. Proteus mirabilis was grown anaerobically in Trypticase Soy broth (Difco) , incubated in Brewer Anaerobic Jars with 80% N2, 10% CO2, and 10% H2.
- Proteus vulgaris was grown in Trypticase Soy broth o aerobically. All cultures were incubated at 35 C. Bacteria were labeled in T. Soy broth supplemented with 5 uCi/ml ⁇ H- Thymidine, harvested by centrifugation, and washed twice with synthetic urine (SU) , pH 5.8. For the adhesion assay, the bacteria were resuspended in SU at a final concentration of 5x10 ⁇ bacteria/ml.
- Sample Preparation Twelve catheter samples were used in these experiments including a silicone control. The samples were sectioned using sheers into 2.5 mm ( ⁇ 0.5 mm) pieces and weighed. For assays utilizing single sections of catheters, one piece of catheter/well was placed in 96 well microtiter plates. For larger volume assays, three sections from each sample were placed in 1.5 ml centrifuge tube.
- Assay After sectioning, the samples were washed with 150ul or 450ul SU (based on volume of assay) . The catheters were incubated with either 120ul or 1.0 ml of the appropriate bacteria at 5 x 10 ⁇ /ml SU, for 1 hour, rotated at 6 rpm, at 35 C. Nonadherent bacteria were removed by washing 3 times with either 150ul or 450ul SU. The samples were transferred to scintillation vials and cpm were determined by means of a Packard scintiliator.
- the data consist of bacterial counts (xlO ⁇ ) on the surfaces of four different samples from each of twelve catheter materials using two bacterial types: P. Mirabalis and P. Vulgaris .
- the counts for the former are an order of magnitude higher than for the latter and they will be analyzed separately.
- the sample coding is the same for both data sets and is presented in Table IV.
- Two of the catheter materials i.e., silicone and Teflon coated latex
- the data was analyzed using the Systat statistics software package, version 4.0.
- the only pattern that is repeated here compared to the P. Mirabalis results is that sample 8, the quinoline derivative nitroxolin, again showed the lowest adhesion, and the Ag-nylon/C/Hypol (sample 6) also performed well with both organisms .
- Selected samples were rerun using larger sample pieces in order to increase the bacterial count and achieve greater precision. The results are plotted in Fig. 8. This set included nylon/C/Hypol control. ANOVA analysis shows a significant difference among these samples as might be expected (p ⁇ 0.02) .
- the silicone and Teflon/latex controls appear to cause much greater adherence than any of the samples coated in accordance with the present invention.
- the difference between the combined controls and the combined samples coated in accordance with the present invention is highly significant (p ⁇ 0.01) .
- the bacterial adhesion is significantly less (p ⁇ 0.03) than the control with only nylon/C/Hypol.
- Ag alone or ethylene diamine tetraacetic acid alone does not show significant difference in adhesion compared to the samples not containing these (p > 0.05) .
- the second set of data generally confirm the conclusions from the first study.
- cyanogen bromide may be used instead of cyanuric chloride as the coupling agent.
- the lenses were exposed to a clear 2-5% w/v solution of diaminopropanol tetracetic acid in 0.05 M sodium hydroxide at about pH 7-8. In these experiments, other aminopolycarboxylic acids such as iminodiacetic acid can also be used.
- the lenses were rinsed with distilled water several times . The lenses were then soaked in a solution containing polymyxin sulfate 5 mg/milliliters, for fifteen minutes. The lenses were then rinsed several times with distilled water and stored in commercial lens storage solutions.
- Hypol R hydrophilic polyurethane prepolymer
- Thin uniform coatings were obtained with some practice.
- the coated lenses and appropriate controls were then immersed in a buffered saline solution, coded (to ensure a blind test) , and stored for further tests.
- P. aeruginosa 6294 (from a human corneal ulcer) stored in tryptic soy broth and 10% glycerol at -70 C was used as the bacterial strain.
- Each contact lens was divided aseptically (laminar flow hood) in half with a sterile razor blade in order to perform duplicate experiments .
- the divided half lenses were incubated statically in 1 ml bacterial suspension for 1 hour at room temperature. After incubation, the lenses were profusely rinsed in six aliquots of PBS to remove all firmly attached bacteria. The lenses were then ground with a glass rod and suspended in 10 ml of PBS. The suspension was diluted in 1:10 serial dilutions and cultured on TSA plates. o The plates were incubated for 36 hours at 37 C.
- Colony growth was counted and the number of bacteria per half lens was calculated and expressed as colony forming units (cfu) per half a contact lens .
- cfu colony forming units
- Test Results The duplicate set of results of bacterial adhesion expressed as average cfu and % adherence are shown in Table V.
- the antimicrobial activity of the contact lens storage solutions is shown in Table VI. TABLE V. BACTERIAL ADHESION RESULTS OF SURFACE TREATED CONTACT LENSES
- Control 20 100 9.5 100
- PBS phosphate buffered saline
- CC cyanuric chloride
- PEO polyethylene oxide
- EDTA ethylene diamine tetraacetic acid
- RMA resorcinol monoacetate
- Control 235 100 103 100 polymyxin dipped 2.28 1 0.17 0.2 (Example 11) polymyxin coupled 122 52 62 60 (Example 12)
- Table VII clearly shows the superiority of polymyxin dipped lenses. This is a simple process that results in the ionic bonding of the antibacterial on the contact lens surface.
- the lens storage solution from this example showed some bactericidal activity (11.7 x 10 4 cfu/ml vs. 1.05 x 10 4 cfu/ml for the control) indicating an equilibrium between the adsorbed polymyxin and the solution.
- the distilled water rinsed contact lenses were soaked in 1% cyanuric chloride in acetone, followed by exposure to a DPTA solution (3.66 grams of DPTA + 2 grams of sodium hydroxide + 100 ml of distilled water) , followed by exposure to polymyxin B sulfate solution (0.1 g/50 ml water) .
- the bacterial adhesion results from these lenses are shown in Table VII.
- the lenses show 50-60% adherence compared to the control.
- the incomplete bacterial inhibition in this example is attributed to the partial coverage of the lens by the immobilized polymyxin. Such incomplete coverage can be remedie s by careful control of pH. However, the important observation in this experiment is the solution activity of these lenses.
- the lens storage solutions did not show any bactericidal activity (Control solution: 1.05 x 10 8 cfu/ml vs solution from this example: 0.66 x 10 8 cfu/ml) .
- the lack of bactericidal activity in the storage solution shows that the polymyxin is strongly bound to the surface.
Abstract
Disclosed is an encrustation and bacterial-resistant coating for use on medical devices and in other medical-related applications. The coating includes a reaction product formed by the covalent linkage of a hydrophilic polyurethane prepolymer and aminopolycarboxylic acid. An urease inhibitor and/or an antibacterial agent may also be added to the coating.
Description
ENCRUSTATION AND BACTERIAL RESISTANT COATINGS FOR MEDICAL APPLICATIONS
BACKGROUND OF THE INVENTION
This invention has been developed in part with funding provided by the National Institute of Health pursuant to NIH SBIR Phase I Grant R43DK43589-01.
This invention relates to medical devices that are resistant to bacterial growth or encrustation such as a) urinary catheters and more particularly to urinary catheters constructed of a material which enables the urinary catheters to inhibit urease and to prevent calcium and magnesium phosphate deposits on the catheters and b) contact lenses, more particularly to extended wear lenses coated with a suitable material to enable the lenses to resist the adherence of microorganisms. urinary Catheters: Catheters are used in urological surgery and when other methods of managing urinary- incontinence fail. These catheters are generally made from a non-toxic, non-irritating material which is flexible but which will withstand collapse. Ideally they should resist colonization by bacteria and encrustation by mineral deposits.
The most common materials used for the catheters are latex, plastic or silicone. All biomaterials, including the most recently tested polyurethane, polyurethane-carbon and silicone-carbon, become encrusted with mineral deposits to varying extents . The degree of encrustation formation on biomaterials exposed to urine is dependent upon the biomaterial, the length of urinary exposure, the presence of infection and the solute content of urine. Several independent studies (e.g. Hukins et al., 1989) of the scraped encrusted material have identified -- two major salts, namely apatite Ca5(Pθ4)3 (OH) and struvite Mg
NH4PO4 6H2O. A very small amount of brushite C HPθ4.2H2θ has also been identified. Apatite is precipitated from urine under alkaline conditions (pH=9.2) along with struvite. Brushite with a Ksp of the order of 10"5 is not stable above pH=7; but is precipitated below 6.5.
The pH increase of urine occurs due to urease producing bacteria, that infect the urine. Urease catalyzes the hydrolysis of urea at an enormous rate (lθl times as fast as the spontaneous hydrolysis of urea which is not observable in neutral solution) producing ammonia, which in turn precipitates calcium phosphates.
Microbial heterogeneity and structural complexity of the bio-films observed on infected catheter materials by means of scanning and transmission electron microscopy reveal a variety of microflora. It appears that the adherent microcolonies of bacteria are much less susceptible than their planktonic counterparts to antibiotics because the extensive anionic matrix surrounding the cell appears to comprise an ion exchange barrier between charged antibiotic molecules and their cellular targets. Antibiotics should be reserved for symptomatic, febrile infections; otherwise their use produces a change in bacterial flora with the potential for producing resistance.
Bacteriurea in a catheterized patient indicates the urinary tract has become colonized or infected. Administration of anti-bacterials such as nitrofurantoin, methenamine, and naldixic acid are used in practice. Most of these are not very effective in alkaline urine, and to achieve a high concentration in urine, the patient has to be given enormous doses.
Catheter associated bacteriurea results from ascending bacterial colonization within glycocalyx enclosed biofilm on the inside and/or outside surfaces of the catheter and drainage systems. Urinary tract catheters made from a
biomaterial that inhibits bacterial adherence and thus retards upstream colonization of bacteria may reduce acquired urinary tract infection (UTI) . While hydrophilic surfaces show reduced protein adhesion, antibacterial surfaces offer better protection. Either a controlled release or an antibacterial immobilized on the surface should offer continuous protection against bacterial colonization. A silver oxide catheter is described in a publication by Shaeffer, A.J., Story, K.O., Johnson, S.M. in "Effect of silver oxide/Trichloroisocyanuric Acid Antimicrobial Urinary Drainage System on Catheter Associated Bactiurea, " J. Urol., 39, 60 (1988) . A recent clinical study on silver catheters reported by Johnson, J.R. , Roberts, P.L., Olsen, R.J., Moyer, K.A. , and Stanni, W.E. in "Silver Oxide Coated Catheters," J. Infect. Diseases, 162, 1145 (1990) indicated the prevention of UTI among women not receiving antimicrobials.
The other problem associated with catheters left in place for long periods of time is the encrustation due to the formation of calcium hydroxyapatite and struvite. Long- term urethral catheterization is frequently necessary for patients with intractable urinary incontinence or retention. This procedure is employed in as many as 16-28% of patients in various chronic care facilities. More than 50% could suffer from blockage of their catheters . This can cause incontinence due to urinary bypassing of the catheter or acute pain and discomfort associated with urinary infection. This is particularly distressing for patients being cared for in the community where professional help is not immediately available. In addition, the coarse irregular surface may result in pain and physical trauma when the catheter is removed increasing the risk of infection.
Removal of deposits by acidic solution (citric acid- magnesium oxide) has been shown to dissolve encrustation in vi tro and is now used extensively in practice. Frequent irrigation could result in the damage of the mucus in the bladder.
The patent literature abounds with patents on indwelling urinary catheter systems aimed at preventing urinary tract infection. These are mechanical devices with appropriate valve fittings to keep the drainage open at the same time preventing ascending infection. U.S. Patents 4,946,449 issued to Richard Davis and 4,878,901 issued to Hans Ernst Sachse are two typical examples. However, these do not have any prevention methods for encrustation. In general, mechanical systems are complicated and do not provide adequate protection from infection. U.S. Patent 4,932,948 issued to Kernes et al., discloses the use of a funnel shaped insert at the end of the urinary catheter that serves as a reservoir to antimicrobial agents. The antimicrobial agent is simply mixed with the ethylene/vinyl acetate polymer during the fabrication of the funnel. The catheter surface itself does not carry any antimicrobial nor is it capable of preventing encrustation. U.S. Patent 4,579,554 issued to Jacob Glassman discloses a design that provides for irrigation of the catheter tube. Frequent irrigation, however, could result in the damage of the mucus in the bladder.
U.S. Patent 4,642,104 issued to Sakamoto et al. , teaches the use of polymers carrying multicarboxyl, amino or sulfonic acid group capable of binding antibiotics through ion exchange. The ion exchange groups are chemically introduced into the molecules of the inside and outside wall of the urethral catheter by hydrolysis of certain functionalities that are present in the polymer that is coated on the surface of the catheter. Cationic antibiotics
such as polymyxins or soap preparations such as benzalkonium chloride or benzethionium chloride, cyclohexidine or povidine-iodine remain on the surface due to the electrostatic binding.
U.S. Patent 4,950,256 issued to Luther et al. , teaches the use of an intravascular catheter comprising a cannula for insertion into a vascular system of a patient. This catheter is coated with a hydrophilic polyurethane-polyene composition for binding antithrombogenic materials and cationic polymyxin antibiotics . Luther et al . , show that the absorption of the polymyxins into the hydrophilic polyurethane can be controlled by varying the initial concentrations . The authors describe this as a time release intravascular catheter. The present invention differs from that of Luther et al. , by virtue of the immobilization of polymyxin through a binding action with the dianionic diaminopropanol tetraacetic acid (DPTA) groups.
Contact Lenses: Infective ulcerative keratitis is one of the most severe hazards of hydrogel extended wear soft contact lenses (SCLs) . The extent of bacterial adherence varies with the nature of the base materials, protein deposits and surface charges. While the mechanism of adhesion and colonization of bacteria on SCLs is not well understood, the influence of adsorbed proteins has been implicated. Recently it was reported ("Pseudomonas attachment to low-water and high-water and non-ionic, new and rabbit worn soft contact lenses," Brussel et al., Investigative Ophthalmology and Visual Science, 32, 657, 1991) that both new and worn SCLs can bind amounts of P. aeruginosa that could potentially produce bacterial keratitis.
SCLs in the eye are readily coated with tear proteins, mucus and lipids (Tripathy et al. , "Lens Spoilage in Contact Lenses, " in The CLAO guide to basic and applied clinical
practice, " Dabecies O.H. Jr. (Ed), Grune and Stratton Inc., Orlando Fl, 1984) . P. aeruginosa is the responsible microorganism in up to two thirds of the reported cases of extended wear SCL associated infectious keratitis . The extended wear contact lens induces corneal hypoxia, microtrauma and tear film destruction that weaken corneal defense.
It is therefore a principal object of the present invention to provide a catheter for use in urological surgery or for managing urinary incontinence which inhibits the build up of encrustation on the surface of the catheter.
Another object of the present invention is to provide a catheter for use in urological surgery or for managing urinary incontinence which causes a lower risk of infection than known catheters.
It is yet another object of the present invention to provide a coating for contact lenses, particularly of the extended wear type, which inhibits the adhesion of harmful bacteria on the lens surface.
SUMMARY OF THE INVENTION There is a clear need to develop biopolymeric interfacial surfaces which minimize bacterial adhesion. The present invention describes such a surface with two specific examples : one a urinary catheter and another a contact lens. Urinary catheters of the present invention are made of materials that a) prevent the adherence of bacteria, b) inhibit urease, and c) prevent calcium and magnesium phosphate deposits on the material. Such urinary catheters are especially useful when intended for use for extended periods. The invention includes the surface modification of, high surface area carbon by means of a reactive hydrophilic polymer which forms a composite when painted on a braided nylon. The carbon modified polymer paint can be coated on
all plastic materials including latex. The coated catheter remains flexible and hydrophilic and allows equilibration of ions and offers a reactive surface. This invention has been extended to apply to contact lenses. Lenses coated with carbon-free formulations of the present invention show excellent resistance to P. aeruginosa . Certain chemical modification schemes of the surface of the contact lens were also successful.
The present invention differs from the prior art in several ways: 1) it uses antibacterials that could covalently bind to the -NCO group of a prepolymer such that the antibacterial would become a part of a hydrophilic polyurethane backbone of the coating, 2) it uses an oxidized high area carbon which is extremely effective in binding Ag+ ions and antibacterials such as polymyxin through its carboxylic groups . The C00~ groups can also bind cationic ingredients such as aminopolycarboxylic acids and their derivatives capable of chelating Ca2+ and Mg2+ coupled with Ag+ which is a urease inhibitor along with antibacterials such as fluoroquinolones, quinolones and other antibacterials make the coating of the present invention a triple defense system. 3) It uses cyanuric chloride (trichloro-s-triazine) as a coupling agent to react with hydroxyl groups on surfaces.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a sectional view of the coating configuration of the present invention.
Fig. 2 is a perspective view of apparatus used to study the encrustation of urinary catheter samples coated in accordance with the present invention.
Fig. 3 is a graph showing encrustation weight per unit area, for the Urease Encrustation Model in which the Y-axis
on the left shows weight rationalized on the basis of geometric area and Y-axis on the right shows the data for real surface area.
Fig. 4 is a graph showing encrustation weight per unit area, for the Bacterial Encrustation Model in which the Y-axis on the left shows weight rationalized on the basis of geometric area and Y-axis on the right shows the data for real surface area.
Fig. 5 is a plot of bacterial adhesion data for P. Mirabalis for all samples including the silicone and Teflon controls.
Fig. 6 is a plot of bacterial adhesion data for P. Mirabalis for the samples from the present invention only.
Fig. 7 is a plot of bacterial adhesion data for P. Vulgariε for all samples including the silicone and Teflon controls.
Fig. 8 is a plot of bacterial adhesion data for P. Vulgaris for selected samples along with the controls.
Fig. 9 is a graph showing the effect of different treatments on the bacterial adhesion on IV catheter materials.
Fig. 10a is a perspective view of a contact lens.
Fig. 10b is a cross sectional view of the lens shown in Fig. 10a.
Fig. 10c is an expanded schematic of the covalent coupling of diaminopropanoltetra acetic acid to the lens surface through a bridge of cyanuric chloride.
Fig. lOd is also a cross sectional view of the contact lens of the type shown in Fig. 10a.
Fig. lOe shows an enlarged view of a thin coating of HypolR/Polyox^ coating as explained in Example 10.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following is a detailed description of two embodiments of the present invention:
Urinary Catheter: The coating for catheters of the present invention that minimizes encrustation and/or infection, as encountered in known urinary catheters includes a coating having a hydrophilic polyurethane pre¬ polymer, a high area filler which is preferably carbon (but silica or alumina and other agents may be used which chelate calcium and magnesium in the body fluids that cause encrustation) , anti-bacterial agents such as quinolones and urease inhibiting agents such as silver ions and EDTA.
Aminopolycarboxylic acids such as ethylene diamine tetraacetic acid, and iminodiacetic acid are powerful chelating agents for Ca and Mg at pH's between 8-10. At pH=7, (the normal urine pH) , ethylene diamine tetraacetic acid exists mostly in the form of H2 Y2~ (Y4- is the tetra ion) and small amounts of Y4-, H3 Y~ and H4 Y. At pH 10, the concentration of Y4_ is 40% of the total concentration of the ethylene diamine tetraacetic acid. In a situation where H2 2~ is present on the biomaterial in reasonably high concentration, the increase in pH due to urease action will be somewhat controlled due to the release of the acidic protons and any further increase would result in the formation of Y4- which will engulf Ca2+ and Mg2+ at pH values between 8 and 10 and prevent the nucleation of hydroxyapatite and struvite on the catheter surface. When the pH of the urine becomes 7, the bound calcium and magnesium are released by ethylene diamine tetraacetic acid. It must also be noted that when the pH of the urine approaches 5 or below, ethylene diamine tetraacetic acid can act as powerful urease inhibitor and also possesses antibacterial properties by chelating Ca2+ from the cell wall. Therefore the advantages of using ethylene diamine
tetraacetic acid and related ligands at both high and slightly below neutral pH are highly beneficial in achieving the goals described above.
Among the antibacterial agents the quinolones are currently undergoing more innovation, and the interest far exceeds that in the cefalosporins and aminoglycosides. The quinolones are bactericidal and the minimum inhibitory concentration, in general, increases in presence of divalent cations due to their tendency to form complexes. The use of resorcinol or resorcinol monoacetate antiseptic agent has already been established for external uses. Incorporation of resorcinol monoacetate in collagen based biomaterials show dramatic evidence of bacterial inhibition even at a 2% w/w concentration. When this functionality is bonded to the catheter surface, one might expect to see long-term antibacterial effects.
In order to enrich the surface by the organic functionalities, a polymer was used. Extensive search of different commercially available polymers revealed the availability of a hydrophilic polyurethane prepolymer sold by W.R. Grace under the trade name HypolR. Hypol 5000 (a pale yellow, high viscosity liquid) which is a MDI based prepolymer that contains 2.55 meq/g of free -NCO group and its various reactions with -OH and -COOH groups are shown below.
R-N=C=0 + R'OH === R-NH-C-OR'
I I
0 R-NCO + R'-COOH > R-NH-CO-R' + C02 (amide)
The highly reactive -NCO groups were reacted with ethylene diamine tetraacetic acid, iminodiacetic acid, resorcinol monoacetate, and quinolones. While several
reaction sequences with different rate constants are possible during the coupling and curing processes, IR spectral data indicates the absence of -NCO groups and the presence of urethane, -COOH and -OH groups in the cured sample.
High area carbon can be used as an excellent support material for polymers such as Hypol. Diluted Hypol after chemical coupling with the appropriate compound blends very well with hydrophilic Cabot M-1300 carbon and forms a paint¬ like formulation. The surface area measurements of carbon loaded with Hypol tubings after complete cure showed an area of 3000 cm2/g. The surface area of a silicone tube used as control in the experiments was only 270 cm^/g. Thus the use of high area carbon in the formulation allows surface concentrations of the chelating and anti-bacterial agents to be at least one order of magnitude higher than what would be possible without the carbon. Hypol also proved to be an excellent binder for carbon and during all incubation studies of the various Hypol/Carbon catheter materials, microscopic carbon particles were not detected.
Once the modified Hypol (5-15% w/v in acetone) is diluted with dry acetone, addition of small amounts of Poly- Hema (4 ml of 12% w/v polyhydroxyethyImethacrylate in ethyl alcohol) and polyethyleneoxide, 300,000-9,000,000 molecular weight (2 ml of 5% w/v solution in methylene chloride) results in homogeneous dispersions . The resulting coatings showed greater lubricity and flexibility when exposed to water.
The high surface area of the carbon (>50 sq.m/g) coupled with its ability to provide reactive surface groups for the attachment of various ligands would facilitate a high surface concentration of the ligand moieties.
The urease concentration on the surface will be of micromole quantities . The aminopolycarboxylic ligands are
capable of reversibly binding Ca2+ or Mg2+ depending upon the pH. Also the high surface concentrations of powerful urease inhibitors, such as Ag+ along with antibacterials are expected to provide a powerful barrier against infecting bacteria and urease. The equilibration between the surface and the urine must be rapid due to the expansion of the hydrogel or ionomer coatings allowing diffusion of various species .
Nylon 6,6 fibers are used as support for the Hypol- carbon coatings; this support material allows the construction of tubings with different formulations and serves as a basis for proving the feasibility of this approach. The coated tubes can themselves be used as collapsible catheter material, although, several other designs are possible. An Ag-nylon material has also shown excellent adhesion to Hypol-carbon paint compared to plain nylon 6,6. The results also show better microbial protection when Ag-nylon is used in combination with ethylene diamine tetraacetic acid. The nylon/HypolR tubing were quite rigid, and would not collapse under normal usage.
The coating configuration is shown in Figure l as a longitudinal cross section of a portion of the catheter tube 10. The cross-hatched portion 11 is the nylon weave which is braided onto a plastic core (not shown) . This core is removed after the coating process to obtain the catheter tube 12. The granular material 14 shown in Fig. 1 in the nylon braid 15 represents the carbon black. The nylon braid 15 is completely covered with the Hypol/carbon paint 16. All the coatings were moisture cured overnight at room temperature and the coated tubes were stored at room temperature.
The term incorporation implies special methods of covalent attachment of the reagents on high surface area carbon followed by hydrogel encapsulation of carbon. Active
carbon has been successfully encapsulated and has been used in the removal of toxins from blood. The hydrogel coatings reinforced with carbon and nylon fibers show superior mechanical strength compared to pure hydrogel coatings.
Contact Lens Application: Infective ulcerative keratitis is one of the most severe hazards of hydrogel extended wear soft contact lenses . Three new approaches are presented here to overcome this problem.
The first approach is based on the reactivity of trichloro-s-triazine (cyanuric chloride) toward -OH groups on the soft contact lens material surface. Cyanuric chloride (CC) as a coupling agent has been used in certain controlled delivery systems and has been proven to be safe (Petrak, K. , 'Pharmaceutical Applications of Functionalized Polymers', in Reactive Polymers, vol. 10, page 231, 1989) . Even though cyanuric chloride is toxic due to the active chlorine, once the chlorides are coupled to IDA or EDTA moieties, the resulting structure is inert and non-toxic. The resulting ether linkages are inert to hydrolysis. In the present invention, chemical modification procedures will initially prepare in si tu IDA or DPTA-CC which will be further reacted with SCL. The CC-IDA or CC-DPTA aqueous solutions have no odor and can be easily handled. This treatment will result in the formation of a layer of covalently bound active functionalities. The coverage on the surface of the contact lens will be at monolayer levels .
A schematic illustration of the coating process is shown in Fig. lOa-lOc. Fig 10a shows a side view of the surface modified contact lens. Fig. 10b is a cross sectional view of the lens. Fig. 10c shows an enlarged view of the binding of the DPTA or IDA to the lens surface through cyanuric chloride bridge. Such treatments and covalent linking can also be achieved using cyanogen bromide or cyanogen chloride as the coupling agent.
Covalently bound chelating agents like DPTA could still bind Ca2"1" and disrupt the cell wall of the bacteria. The same chelating effect is expected of iminodiacetic acid which readily bonds to CC. These bactericidal agents, functioning by their cation complexing action upon the cell wall do not need to be incorporated into the bacterial cell to be effective as bactericides. As an added protection, a water soluble antibiotic such as polymyxin sulfate B (a large cation) can be bound to the C00~ rich surface. (This antibiotic is presently used as a topical medication for contact lens related infections) .
Polymyxins are one among the very few antibiotics which are known to inhibit P. aeruginosa . The group of polymyxin includes closely related circulins and colistins . These are closely related to cyclic lipopeptides. They are branched cyclo- octa, deca or undeca peptides that are monoacetylated in the aminoacyl side chains with branched chain fatty or B-hydroxy fatty acids. These antibiotics are characterized by a high percentage of a, r- diaminobutyric acid, the presence of several aminoacids and a heptapeptide ring and by the fatty acid attachment to the N-terminal of the peptide side chain through an amide bond. The polymyxins are deca-peptides containing Cg or C9 fatty acids.
The second approach is based on the discovery that polymyxin sulfate B is capable of adsorbin on the polyhema surface of the contact lens. There is evidence in the literature on the irreversible adsorption of different drugs on the poly-HEMA surface. In the present invention, it was found that polymyxin B sulfate in contact with the surface of the Surevue lenses, was irreversibly bound. This discovery is further explained in Example 11, where it is shown that after treatment with polymyxin B sulfate, and several rinses of the lens, no bacterial adhesion is found.
Our invention that polymyxin B is extracted by poly- hema contact lens and retained after several washings can be explained on the basis of solubilities of various lipophilic drugs in p.hema. Drugs such as chloramphenicol, pilocarpine, dexamethasone etc., were found to have a longer washout period when entrapped in intraocular lenses (T.P. Heyrman, M.L. McDermott, J.E. Ubels and H.F. Edelhauser, in Journal of Cataract Refractory Surgery, vol 15, page 169, 1989) . Gentamicin soaked contact lenses made of 61.4% p.hema hydrogel were found to retain bactericidal concentrations of the antibiotic for three days of eye contact (M. Busin, M. Spitznes, Ophthalmology, vol 95, page 796, 1988) . Ionic binding of cationic polymyxin by the anionic carboxyl groups is also possible.
In another approach, an optically clear, adherent coating can be obtained using HypolR in combination with small amounts of polyethylene oxide with or without antibacterials. A schematic illustration of such a coating is shown in Fig. lOd, with Fig. lOe showing an enlarged view of the coating on the lens surface. The cured coatings incorporate, by covalent bonding, the organic functionalities in the polyurethane backbone. The pre¬ polymer polyurethane forms a clear, highly adherent, hydrophilic coating on the soft contact lenses.
EXAMPLE 1
10 g of Hypol 5000 (a hydrophilic polyurethane prepolymer, MDI based, 2.5 meq. NCO per gram, W.R. Grace) was weighed into a polypropylene cup and 5 mmoles each of ethylene diamine tetraacetic acid, iminodiacetic acid, resorcinol monoacetate, and nitroxolin were added, and stirred well. To this mixture was added dry methylene chlo¬ ride (70 ml), a few drops of a surfactant, Pluronic L-101. The mixture was homogenized with a homogenizer or
sonicator and used for coating after the addition of dry carbon (Carbon black, M-1300, Cabot Co., 7 g) . Desired consistency is obtained by the addition of more solvent. All formulations hardened within 2-4 hrs. The coatings con¬ sisted of a) Hypol-ethylene diamine tetraacetic acid/C b) Hypol-resorcinol monoacetate/C c) Hypol-Nitroxolin/C and d) Hypol-iminodiacetic acid/C. Coatings were done using a dip coating machine on pretreated nylon 6,6 fibers and silver nylon (Charles Reiner Co) fibers. A smooth uniform tube of approximately 2.5mm diameter is obtained, which is used in the experiments described in Examples 2-8.
EXAMPLE 2 Magnesium Binding Capacity of the Coated Surfaces:
Typically 6" long coated tubes were incubated in an ammonium chloride/ammonium hydroxide buffer (pH=10) containing 0.04 M of Mg. After four hours of incubation, the samples were rinsed with ammoniacal water and the solution was titrated against standardized ethylene diamine tetraacetic acid. The ethylene diamine tetraacetic acid immobilized surface showed a magnesium uptake of 0.31 mmoles in excess of what was absorbed by a sample not containing immobilized ethylene diamine tetraacetic acid.
EXAMPLE 3
3" samples of the materials were soaked in 30 ml of synthetic urine (pH=5.8) for 2.5 hours, after which 25 units o of urease solution was added and maintained at 37 C over¬ night.
For all the urease inhibition experiments, synthetic urine was used. Synthetic urine was prepared as described in Griffith, D.P., Musher, D.M., and Itin, C, "Urease -- The Primary Cause of Infection Induced Urinary Stones, "
Investigative Urology, 13, 346 (1974) with the following composition (Table I) .
TABLE I. COMPOSITION OF SYNTHETIC URINE (Griffith et al., 1976)
Chemical Concentration (g/L)
CaCl2.2H20 0.65
MgCl2.6H20 0.65
NaCl 4.60
Na2c2°4 °-02
KH2P0 2.80
KC1 1.60
NH C1 1.00
Urea 25.00
Creatinine hemisulfate 1.10
Uric acid 0.25
Bovine Serum Albumin 0.50 pH adjusted to 5.80
TABLE II. RESULTS OF OVERNIGHT INCUBATION OF CATHETER TUBE SAMPLES (3") IN SYNTHETIC URINE CONTAINING UREASE.
Sample # Description Observation
1A nylon 6,6/C/Hypol/ dense precipitate
11 nylon 6, 6/C/Hypol-EDTA moderate precipitate
3A nylon 6, 6/C/Hypol-IDA moderate precipitate
6 Ag-nylon/C/Hypol dense precipitate
3 Ag-nylon/C/Hypol-IDA very small amount of ppt, pH = 7.06
Ag-nylon/C/Hypo-EDTA Clear Solution pH 6.88
The polymer bound chelating agents (ethylene diamine tetraacetic acid, iminodiacetic acid) show almost no precipitation of Ca and Mg.
EXAMPLE 4
3" samples of the materials were soaked in 30 mL of synthetic urine for 2.5 hours and varying amounts of urease o solution was added and incubated at 37 C for 48 hours.
TABLE III. RESULTS OF INCREMENTAL ADDITIONS OF UREASE TO SYNTHETIC URINE (37 C) CONTAINING SAMPLES (3") AS DESCRIBED
Sample # Description Units of urease Final pH
2 Ag-nylon/C/Hypol-EDTA 25 6.88
3 Ag-nylon/C/Hypol-IDA 25 7.06
1A nylon/C/Hypol 25 8.64
6A Ag-nylon/Hypol 25 8.46
6 Ag-nylon/C/Hypol 25 7.22
2 Ag-nylon/C/Hypol-EDTA 25 7.06
6B Ag-nylon 25 8.74
Silicone control 55* 9.13
1A nylon/C/Hypol 55* 9.10
6 Ag-nylon/C/Hypol 55* 8.47
2 Ag-nylon/C/Hypol-EDTA 55* 7.16
6A Ag-nylon/Hypol 145* 8.46
6 Ag-nylon/C/Hypol 145* 8.62
2 Ag-nylon/C/Hypol-EDTA 145* 7.39
6B Ag-nylon 145* 8.74
* — in increments of 30 units per day.
The data in Table III shows that the polymer bound chelating agents (ethylene diamine tetraacetic acid, IDA) show minimal rise in pH, and the solutions show little
precipitation in these cases. Sample # 2, 3 & 6 (for 25 units of urease only) samples clearly stand out with pHs in the range 6.8-7.5; sample # 2 is particularly good, since the solution containing this sample remained clear, even when the pH rose to 7.8.
EXAMPLE 5
This is a slight variation of Example 4. 40 units of urease was added to 20 mL of synthetic urine (pH=5.8) and incubated at 37 C for 1 hour. The solution became turbid; two portions of this turbid solution were used to incubate 3" samples of 1A (Hypol/C/nylon 6,6) and 11 (Hypol-ethylene diamine tetraacetic acid/C/nylon 6,6) overnight. Sample containing 1A shows a pH of 9.1 with dense precipitate. Sample containing 11 showed an almost clear solution with a pH of 8.0.
The results shown above prove the chelating ability of ethylene diamine tetraacetic acid is retained when it is bound to a polymer backbone as evidenced by its ability to dissolve calcium precipitate formed at pH's above 8. The dissolution process is slow (6-8 h) . This observation is supported by the data in the literature (Burns, J., and J.G. Gargill, "Kinetics of Calcium Oxalate Calculi with Calcium Chelating Irrigating Solutions, " J. of Urology, 39, 530 (1987)) on the kinetics of dissolution of calcium oxalate by ethylene diamine tetraacetic acid: it is reported that the rate of dissolution is slow even when sodium ethylene diamine tetraacetic acid is in solution. However, for a surface containing immobilized ethylene diamine tetraacetic acid rapid nucleation of hydroxyapatite will be prevented at least near the immediate vicinity of the surface, due to presence of the following equilibrium:
Ag > Ag+
Ag+ + EDTA > AgEDTA (surface) pKf = 7.32 @ pH=7.5
Ca2+ + AgEDTA ==== CaEDTA + Ag+ pKf = 10.69 @ pH=7.5
Ag+ + urease > deactivated urease
EDTA + urease > deactivated urease (pH < 6.5)
EXAMPLE 6
The apparatus 22 used is shown in Fig. 2. Artificial urine was added into an experimental vessel 24 (where the catheter tubes 26 were suspended) . The vessel should have an inlet 28 and an overflow outlet 30. A vent 32 is also provided. The experimental vessel 24 was gently stirred o with magnetic stirrer 34 while incubating at 37 C. The catheter samples were suspended in artificial urine for eighteen days. 200 units of urease were added per day and the urine changed every day. The addition of urease was carried out in increments of 50 units/2hr. using a plastic syringe. (The urease solution was prepared by dissolving urease tablets in 10 L sodium phosphate buffer, pH = 7.1) .
In all tests, there were no signs of encrustation for about
1 week after which light white deposits started appearing on the surface. Perhaps due to the stirring no crystalline material was seen. Instead amorphous, loose deposits were seen. At the end of eighteen days, the sample tubes were carefully rinsed with deionized water and carefully dried after putting the individual pieces in pre-weighed clean vial. This ensured the loss of powdery deposits after drying. The dried samples were dessicated before weighing.
After the weight of the encrusted tube was obtained, the tube was immersed in dilute HCl for about 2 minutes, dried o with paper towel and then in an oven at about 50 C overnight. An activated molecular sieve dessicant was kept in the oven to ensure the removal of moisture.
Samples tested using the urease encrustation model per the procedure of Cox, A.J., Hakins, D.N.L., and Sutton, T.M., "Comparison of in vi tro Encrustation on Silicone and Hydrogel Coated Latex Catheters, " Br. J. of Urology, 61, 156 (1988) were chiefly urease inhibiting and chelating surfaces . During this experiment the initial pH rise was slow (2 days, 5.8-6.2), and over a period of 14 days rose to 8.3. The initial resistance to pH rise may be attributed to silver ion released from the Ag-nylon in presence of ethyl¬ ene diamine tetraacetic acid. The results of this experiment are plotted in Fig. 3 as weight gained per unit area (mg/cm2) .
The urease addition test model resulted in variable encrustation of all samples in Figure 3. The surface density of the encrustation were calculated based on the geometric area exposed to the synthetic urine. The results clearly show that the ethylene diamine tetraacetic acid modified surface has low encrustation. The results are even more dramatic if the real surface areas are used for calculating the surface density; the best samples constructed in accordance with the present invention show almost an order of magnitude less encrustation than silicone tubing. Visual inspection of the samples showed chunky white deposit on the silicone tube, whereas only a white powdery layer on the samples constructed in accordance with the present invention. It appears that the loose powdery deposits on the materials constructed in accordance with the present invention could easily be washed by the urine flow, whereas the highly adherent deposits on silicone may not come off easily. It appears that the large surface area of the samples of the present invention modifies the nucleation, process resulting in a powdery layer.
The extent of encrustation is clearly related to the presence of antibacterials, chelating agents and urease
inhibitors . An optimum combination of the three could prove better than just one defense mechanism. The extent of encrustation should also be dependent on the surface concentrations of the three classes of compounds. It must be emphasized that the test catheter tubes contained only 0.5 mmoles/g of Hypol in the coating; only two coatings (4 mil total) of this material was loaded on the nylon support.
EXAMPLE 7
For these experiments, a dynamic perfusion model was used. The apparatus 22 used in this example is shown in Fig. 2. Artificial urine was allowed to flow into an experimental vessel 24 (where the catheter tubes 26 were suspended) at a controlled rate (1.2 L/day) . The vessel should have an inlet 28 and an overflow outlet 30. A vent 32 is also provided. Proteus mirabalis was cultured in Trypticase soy broth/urea agar medium by using a cultiloop (BBL labs) . The experimental setup was inoculated with enough bacterial broth to give a turbidity of McFarlane #1 and was checked for bacterial count of lXlO^/mL. The experimental vessel 24 was gently stirred with magnetic o stirrer 34 while incubating at 37 C. Bacterial counts were checked everyday in the outflowing liquid.
The bacterial encrustation model results shown in Fig. 4 indicate that antibacterial agents lower the encrustation more efficiently than chelating agents and urease inhibitors.
The bacterial encrustation along with the urease inhibition study indicate relatively low amounts of encrustation for surfaces modified by ethylene diamine tetraacetic acid. It appears that Hypol bound ethylene diamine tetraacetic acid still maintains its chelating ability. In addition, the large surface area of the carbon loaded polymer coating appears to allow physical deposition
of hydroxyapatite rapidly as the pH rises resulting in a powdery precipitate. The solubilizing action of ethylene diamine tetraacetic acid helps loosen the deposit. It appears that the antibacterial properties of ethylene diamine tetraacetic acid coupled with its ability to chelate Ca + could be advantageously used for catheter coatings . The chief advantage of ethylene diamine tetraacetic acid modified surface is that at pH values below 8, protons compete very efficiently with Ca2+ ions, thus regenerating the surface enriched with uncomplexed ethylene diamine tetraacetic acid. At pH values below 6 ethylene diamine tetraacetic acid complexes nickel centers from urease and thus becomes an urease inhibitor. As the pH of the urine rises due to urease action complexation with Ca + and Mg + occurs with the release of protons . Therefore in the final form the catheters could revive their surface if the patient's urine becomes slightly acidic. Since the inner surface of the catheter is more prone to encrustation, it is possible to incorporate ethylene diamine tetraacetic acid on the inner surface essentially by the same methods .
The outer surface of the catheter could contain simply antibacterials or lower surface concentration of ethylene diamine tetraacetic acid. These tubes can even be used as inner inserts for regular Foley catheters with appropriate redesign.
EXAMPLE 8 Cultures and cultural conditions: Two bacterial strains, Proteus mirabilis and Proteus vulgaris, were used in these experiments. Proteus mirabilis was grown anaerobically in Trypticase Soy broth (Difco) , incubated in Brewer Anaerobic Jars with 80% N2, 10% CO2, and 10% H2.
Proteus vulgaris was grown in Trypticase Soy broth o aerobically. All cultures were incubated at 35 C. Bacteria
were labeled in T. Soy broth supplemented with 5 uCi/ml^H- Thymidine, harvested by centrifugation, and washed twice with synthetic urine (SU) , pH 5.8. For the adhesion assay, the bacteria were resuspended in SU at a final concentration of 5x10^ bacteria/ml.
Sample Preparation: Twelve catheter samples were used in these experiments including a silicone control. The samples were sectioned using sheers into 2.5 mm (±0.5 mm) pieces and weighed. For assays utilizing single sections of catheters, one piece of catheter/well was placed in 96 well microtiter plates. For larger volume assays, three sections from each sample were placed in 1.5 ml centrifuge tube.
Assay: After sectioning, the samples were washed with 150ul or 450ul SU (based on volume of assay) . The catheters were incubated with either 120ul or 1.0 ml of the appropriate bacteria at 5 x 10^/ml SU, for 1 hour, rotated at 6 rpm, at 35 C. Nonadherent bacteria were removed by washing 3 times with either 150ul or 450ul SU. The samples were transferred to scintillation vials and cpm were determined by means of a Packard scintiliator.
The data consist of bacterial counts (xlO^) on the surfaces of four different samples from each of twelve catheter materials using two bacterial types: P. Mirabalis and P. Vulgaris . The counts for the former are an order of magnitude higher than for the latter and they will be analyzed separately. However, the sample coding is the same for both data sets and is presented in Table IV. Two of the catheter materials (i.e., silicone and Teflon coated latex) . are in current clinical use and serve as controls for
comparison with the other experimental materials . The data was analyzed using the Systat statistics software package, version 4.0.
TABLE IV. CATHETER MATERIAL CODES
Sample # Description
1A nylon/C/Hypol/Nafion
1A nylon/C/Hypol
2 Ag-nylon/C/Hypol-EDTA
3 Ag-nylon/C/Hypol-IDA 3A nylon 6, 6/C/Hypol-IDA
4 nylon 6, 6/C/Hypol-EDTA/Nafion
5 nylon/C/Hypol-RMA/Nafion
6 Ag-nylon/C/Hypol 6A Ag-nylon/Hypol 6B Ag-nylon
7 nyIon/C/Hypo1-Bufexemac
8 nylon/C/Hypol-Nitroxolin
9 nylon/C/Hypol-RMA
10 Silicone
11 nylon 6, 6/C/Hypol-EDTA
12 Latex/Teflon
The bacterial adhesion data for P. Mirabalis is plotted in Fig. 5. (An outlier, with a Studentized Residual = 10.08 in sample 1, was removed and not included in Figure 5) . As indicated by ANOVA analysis (P=0), there are significant differences in adhesion between the various samples. Clearly, the two "controls, " code=10 (silicone) and code=12 (latex/Teflon), appear to promote greater P. Mirabalis adhesion than any of the materials coated in accordance with the present invention. This conclusion is confirmed by the
results of a t-test in which the two controls combined are significantly different (P=0) from all the materials coated in accordance with the present invention combined.
The data for the materials coated in accordance with the present invention alone is plotted in Fig. 6 with a reduced Y axis scale to highlight differences between these materials. Several advantages are apparent. First, the highest adhesion results were obtained with sample code=l and sample code=7. However, both are still better than the combined silicone and Teflon controls (t-test, p<0.001) . Second, where a direct comparison can be made, i.e., sample 2 vs. sample 3, the two aminopolycarboxylic acids are clearly similar in bacterial adherence. Third, the quinoline derivative nitroxolin (sample 8) yielded the lowest adhesion results.
The data summary for adhesion to the various samples in Table IV to P. Vulgaris is presented in Fig. 7. In general, the adhesion is much lower than with P. Mirabalis, however, there are significant differences among the samples as shown by ANOVA analysis (P=0) . Sample 1 shows the most bacterial adherence and actually appears greater than the silicone and Teflon controls; however, a t-test does not quite reach significance (P=0.08) . Clearly, samples 2,3,7,9 are within the range of the silicone and Teflon controls and cannot be said to have reduced P. Vulgaris adhesion. Samples 4,5,6, and 8 performed the best of the materials coated in accordance with the present invention, and showed a highly significant difference, compared to the combined controls (P=0.001) . The only pattern that is repeated here compared to the P. Mirabalis results is that sample 8, the quinoline derivative nitroxolin, again showed the lowest adhesion, and the Ag-nylon/C/Hypol (sample 6) also performed well with both organisms .
Selected samples were rerun using larger sample pieces in order to increase the bacterial count and achieve greater precision. The results are plotted in Fig. 8. This set included nylon/C/Hypol control. ANOVA analysis shows a significant difference among these samples as might be expected (p < 0.02) . The silicone and Teflon/latex controls appear to cause much greater adherence than any of the samples coated in accordance with the present invention. The difference between the combined controls and the combined samples coated in accordance with the present invention is highly significant (p < 0.01) . When Ag and ethylene diamine tetraacetic acid are present together, the bacterial adhesion is significantly less (p < 0.03) than the control with only nylon/C/Hypol. However, Ag alone or ethylene diamine tetraacetic acid alone does not show significant difference in adhesion compared to the samples not containing these (p > 0.05) . The second set of data generally confirm the conclusions from the first study.
The above results show that the silver nylon or silver nylon-Hypol combinations do not inhibit urease effectively under the conditions these experiments were carried out. One explanation could be the low concentration of Ag+ further reduced by the formation of AgCl when the samples are incubated in synthetic urine. In the Hypol matrix, it appears that the Ag+ is immobilized in a highly insoluble form. Whereas the Ag nylon/ethylene diamine tetraacetic acid inhibits urease, under the same conditions the silver nylon/Hypol alone without the ethylene diamine tetraacetic acid, does not. The anti-bacterial properties of silver nylon suture and wound dressing materials is based upon the slow release of enough silver ions (which are toxic to bacteria) . Experimental evidences based on extractions of o Ag+ from a given quantity of silver nylon at 37 C prove that
the Ag nylon may function as a reservoir of Ag+ ions (Chu et al., 1988; Tsai et al. , 1987) .
EXAMPLE 9
This example illustrates the use of the invention described above as a paint for various catheter surfaces or devices. Polyurethane tubes (e.g., Tecoflex EG80A) were coated with Hypol/carbon mixtures containing silver acetate, resorcinol monoacetate, and Norfloxacin. P. aeruginosa was used as bacterial strain. The bacteria were labeled with •^H-thymidine. The catheter samples were incubated in growth medium containing the labeled bacteria for 48 hours. At the end of the appropriate incubation period, the samples were washed and assayed using a scintillation counter. The results of bacterial counts for the four samples are compared to the control (polyurethane tube without any coating) in Fig. 9. From the results shown in Fig. 9, it is clear that all the treatments are better than the control.
EXAMPLE 10 Surface Treatment of Lenses: SurevueR contact lenses which are manufactured by Vistakon™ were used in these experiments. In one set of experiments, covalent coupling of DPTA was achieved using cyanuric chloride as coupling agent. Acetone rinsed lenses were exposed to a solution (4- o 5 C) containing cyanuric chloride dissolved in dry acetone
(1-2% w/v) . In other embodiments, cyanogen bromide may be used instead of cyanuric chloride as the coupling agent.
After five minutes, the lenses were exposed to a clear 2-5% w/v solution of diaminopropanol tetracetic acid in 0.05 M sodium hydroxide at about pH 7-8. In these experiments, other aminopolycarboxylic acids such as iminodiacetic acid can also be used. After stirring and soaking for fifteen minutes, the lenses were rinsed with distilled water several
times . The lenses were then soaked in a solution containing polymyxin sulfate 5 mg/milliliters, for fifteen minutes. The lenses were then rinsed several times with distilled water and stored in commercial lens storage solutions. In a separate set, polymer modifications of a hydrophilic polyurethane prepolymer (HypolR) were accomplished using hyaluronic acid, resorcinol monoacetate, NafionR (a cationic resin with sulfonate groups) , and PolyoxR. The lenses were rinsed in acetone three times and then dipped in the following solutions and allowed to dry:
Hypol (5% w/v solution in acetone) alone
100 mL of Hypol 5% in acetone + 2-5 gram of pure resorcinol monoacetate
100 mL of Hypol 5% in acetone + 2-5 g of Nafion 5% w/v in alcohol
100 mL of Hypol 5% in acetone + 2-5 g of Polyox 5% w/v in methylene chloride
100 mL of Hypol 5% in acetone + 1-2 g of Hyaluronic acid in water.
Thin uniform coatings were obtained with some practice. The coated lenses and appropriate controls were then immersed in a buffered saline solution, coded (to ensure a blind test) , and stored for further tests.
Bacterial Adhesion Test Protocol: P. aeruginosa 6294 (from a human corneal ulcer) stored in tryptic soy broth and 10% glycerol at -70 C was used as the bacterial strain.
Approximately 100 ml from a 1 ml aliquot of P. aeruginosa o frozen suspension was thawed and grown overnight at 37 C in a tryptic soy agar (TSA) plate. Few colonies from the TSA plate were suspended in sterile phosphate buffered saline solution to a concentration adjusted spectrophotometrically to about 108 cfu/ml (OD=0.1, = 590 nm, Beckman DU-70
Spectrophotometer) .
Each contact lens was divided aseptically (laminar flow hood) in half with a sterile razor blade in order to perform duplicate experiments . The divided half lenses were incubated statically in 1 ml bacterial suspension for 1 hour at room temperature. After incubation, the lenses were profusely rinsed in six aliquots of PBS to remove all firmly attached bacteria. The lenses were then ground with a glass rod and suspended in 10 ml of PBS. The suspension was diluted in 1:10 serial dilutions and cultured on TSA plates. o The plates were incubated for 36 hours at 37 C. Colony growth was counted and the number of bacteria per half lens was calculated and expressed as colony forming units (cfu) per half a contact lens . For the purpose of normalization of results, the bacterial count observed with each control contact lens (uncoated sample) was taken to represent 100% adherence. The bacterial counts for all the coated samples were then normalized with respect to the control, and the % adherence in each case calculated.
Since the bacterial counts were done in two separate batches, one control for each batch was included to account for batch to batch variations in experimental methodology. After the bacterial adhesion results were obtained, the storage solutions of samples with minimum and maximum adherence along with adequate controls were assayed for their antimicrobial activity. In the case of assays involving storage solutions, an additional control in the form of the PBS buffer solution used in these experiments was included to obtain an idea about the bacterial growth in the medium without the influence of the contact lenses .
Test Results: The duplicate set of results of bacterial adhesion expressed as average cfu and % adherence are shown in Table V. The antimicrobial activity of the contact lens storage solutions is shown in Table VI.
TABLE V. BACTERIAL ADHESION RESULTS OF SURFACE TREATED CONTACT LENSES
EXPERIMENT I EXPERIMENT II
AVERAGE % AVERAGE %
Control 20 100 9.5 100
CC-Hyaluronic acid 19 90 11.1 118
Hypol-RMA 23.8 120 2.1 22.2
CC-PEO 79 400 62 653
Control 25 100 9.7 100
Hypol 20 20 3.8 39
Hypol-Hyaluronic acid 11.2 44 11.6 120
Hypo1-Nafion 15 60 4 41
CC-hydroxyEDTA-Polymyxin 0 0 0 0 (cfu x 102)
Hypol-PEO 1.3 5 2.6 27
TABLE VI. ANTIMICROBIAL ACTIVITY OF THE CONTACT LENS STORAGE SOLUTIONS
LENS STORAGE SOLUTION CFU/mL (xlO5)
24 h incubation
control PBS 3.3 control 0 4.3 control 1 2.9
CC-hydroxyEDTA-Polymyxin 3.5
Hypol-PEO 3.0
Hypol-PEO 3.6
CC-PEO 4.0
PBS = phosphate buffered saline; CC = cyanuric chloride; PEO = polyethylene oxide; EDTA = ethylene diamine tetraacetic acid; RMA = resorcinol monoacetate
It is evident from the above data that the polymyxin treated surface shows almost no adherence and the Hypol & Hypol-polyethylene oxide modified surfaces show greatly reduced adherence compared to the controls.
EXAMPLE 11
Three Surevue lenses were first rinsed in distilled water, followed by dipping in polymyxin sulfate solution (0.1 g/50 ml distilled water) . After 5 minutes, the lenses were rinsed and soaked in distilled water in four different beakers and stored in the contact lens storage solution. When these samples were tested for bacterial adhesion using the same procedure as described in Example 10, we obtained the following results :
TABLE VII. BACTERIAL ADHESION RESULTS OF polymyxin TREATED CONTACT LENSES
EXPERIMENT I EXPERIMENT II
AVERAGE AVERAGE
TREATMENT CFU/Vi LENS ADHER. CFU/ j LENS ADHER. (xlO4) (xlO4)
Control 235 100 103 100 polymyxin dipped 2.28 1 0.17 0.2 (Example 11) polymyxin coupled 122 52 62 60 (Example 12)
Table VII clearly shows the superiority of polymyxin dipped lenses. This is a simple process that results in the ionic bonding of the antibacterial on the contact lens surface. The lens storage solution from this example showed some bactericidal activity (11.7 x 104 cfu/ml vs. 1.05 x 104 cfu/ml for the control) indicating an equilibrium between the adsorbed polymyxin and the solution.
EXAMPLE 12
The distilled water rinsed contact lenses were soaked in 1% cyanuric chloride in acetone, followed by exposure to a DPTA solution (3.66 grams of DPTA + 2 grams of sodium hydroxide + 100 ml of distilled water) , followed by exposure to polymyxin B sulfate solution (0.1 g/50 ml water) . The bacterial adhesion results from these lenses are shown in Table VII. The lenses show 50-60% adherence compared to the control. The incomplete bacterial inhibition in this example is attributed to the partial coverage of the lens by the immobilized polymyxin. Such incomplete coverage can be remedies by careful control of pH. However, the important
observation in this experiment is the solution activity of these lenses. The lens storage solutions did not show any bactericidal activity (Control solution: 1.05 x 108 cfu/ml vs solution from this example: 0.66 x 108 cfu/ml) . The lack of bactericidal activity in the storage solution shows that the polymyxin is strongly bound to the surface.
While the foregoing invention has been described with reference to its preferred embodiments, various alterations and modifications will occur to those skilled in art. All such alterations and modifications are intended to fall within the scope of the appended claims.
Claims
1. A coating for polymeric products used in medical applications, said coating comprising: a reaction product formed by a covalent linkage of a hydrophilic polyurethane pre-polymer and aminopolycarboxylic acid.
2. The coating of claim 1 wherein said aminopolycarboxylic acid is selected from the group of ethylene diamine tetraacetic acid, diaminopropanol tetracetic acid and iminodiacetic acid.
3. The coating of claim 1 further comprising a high area carbon compounded with said coating to provide a larger surface area of contact.
4. The coating of claim 1 further comprising a urease inhibitor.
5. The coating of claim 1 further comprising an antibacterial agent.
6. The coating of claim 5 wherein said antibacterial agent is from the quinolone family.
7. The coating of claim 5 wherein said antibacterial agent is a phenolic compound.
8. A coating for polymeric products used in medical application, said coating comprising: aminopolycarboxylic acid; a coupling agent for directly linking said aminopolycarboxylic acid to at least one surface of the said polymeric product.
9. The coating of claim 8 further comprising a high area carbon compounded with said coating to provide a larger surface area of contact.
10. The coating of claim 8 wherein said coupling agent is cyanuric chloride.
11. The coating of claim 8 wherein said coupling agent is cyanogen bromide.
12. The coating of claim 8 wherein said aminopolycarboxylic acid is selected from the group of diaminopropanol tetracetic acid and iminodiacetic acid.
13. The coating of claim 8 further comprising a urease inhibitor coupled with said aminopolycarboxylic acid.
14. The coating of claim 8 further comprising an antibacterial coupled with said aminopolycarboxylic acid.
15. A medical device which is resistant to the formation of encrustation or bacteria for use in medical applications, said device comprising: a base material formed in a desired shape; a coating covering at least one surface of said base material, said coating including a reaction product resulting from a covalent linkage of said hydrophilic polyurethane pre-polymer with an aminopolycarboxylic acid.
16. The device of claim 15 wherein said coating further comprises a high area carbon compounded with said coating to provide a large surface area of contact.
17. The device of claim 15 wherein said device is a urinary catheter.
18. The device of claim 15 wherein said base material is constructed from silver-nylon fibers.
19. The device of claim 15 wherein said device is a Foley catheter.
20. The device of claim 15 wherein said device is a soft contact lens .
21. The device of claim 20 further comprising an antibiotic or Ag+ ionically bound or a quinolone or fluoroquinolone covalently bound to said aminopolycarboxylic acid or to the coupling agent at a total amount of less than one pre-determined systemic dose.
22. A polymeric device for use in medical applications, said device comprising: a base material formed out of a polymeric material into desired shape; a coating covering at least one surface of said base material, said coating including: an aminopolycarboxylic acid; a coupling agent for directly linking said aminopolycarboxylic acid to at least one surface of said base material.
23. The device of claim 22 wherein said coupling agent is cyanuric chloride.
24. The device of claim 22 wherein said coupling agent is cyanogen bromide.
25. The device of claim 22 wherein said aminopolycarboxylic acid is selected from the group of diaminopropanol hydroxy acetic acid, iminodiacetic acid.
26. The device of claim 22 further comprising an antibiotic ionically bound to said aminopolycarboxylic acid at a total amount of less than one pre-determined systemic dose.
27. The device of claim 22 wherein said device is a contact lens.
28. The device of claim 22 wherein said device is a catheter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67044/94A AU6704494A (en) | 1993-04-16 | 1994-04-14 | Encrustation and bacterial resistant coatings for medical applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/048,489 US5328954A (en) | 1993-04-16 | 1993-04-16 | Encrusting and bacterial resistant coatings for medical applications |
US08/048,489 | 1993-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994024181A1 true WO1994024181A1 (en) | 1994-10-27 |
Family
ID=21954860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/004107 WO1994024181A1 (en) | 1993-04-16 | 1994-04-14 | Encrustation and bacterial resistant coatings for medical applications |
Country Status (3)
Country | Link |
---|---|
US (1) | US5328954A (en) |
AU (1) | AU6704494A (en) |
WO (1) | WO1994024181A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008063206A1 (en) * | 2008-12-29 | 2010-07-01 | Urotech Gmbh | Method for testing different materials on its applicability for the use in products that are to be processed in areas containing a fluid, in urological implant, comprises holding the materials to be tested in the form of longitudinal rods |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5476881A (en) * | 1993-02-15 | 1995-12-19 | Suh; Kang I. | Antimicrobial composition for manufacturing nipples |
SE502620C2 (en) * | 1993-02-26 | 1995-11-27 | Leif Nilsson | urinary catheter |
US6558798B2 (en) | 1995-02-22 | 2003-05-06 | Scimed Life Systems, Inc. | Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity |
US6468649B1 (en) * | 1995-02-22 | 2002-10-22 | Scimed Life Systems, Inc. | Antimicrobial adhesion surface |
US5779943A (en) * | 1996-03-19 | 1998-07-14 | Johnson & Johnson Vision Products, Inc. | Molded polymeric object with wettable surface made from latent-hydrophilic monomers |
US6443942B2 (en) | 1996-11-01 | 2002-09-03 | Minimed, Inc. | Medication device with protein stabilizing surface coating |
US5877243A (en) * | 1997-05-05 | 1999-03-02 | Icet, Inc. | Encrustation and bacterial resistant coatings for medical applications |
EP0991702B2 (en) * | 1997-06-20 | 2017-07-19 | Coloplast A/S | A hydrophilic coating |
DE19729279A1 (en) * | 1997-07-09 | 1999-01-14 | Peter Hildebrandt | Urological implant, in particular vascular wall support for the urinal tract |
US6087415A (en) * | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
CA2345111A1 (en) * | 1998-09-23 | 2000-03-30 | Phycogen, Inc. | Antifouling agents |
US6592814B2 (en) * | 1998-10-02 | 2003-07-15 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with antimicrobial coatings |
US6596401B1 (en) | 1998-11-10 | 2003-07-22 | C. R. Bard Inc. | Silane copolymer compositions containing active agents |
US6473171B1 (en) * | 1999-01-15 | 2002-10-29 | Coors Brewing Company | Biocompatible apparatus for ultrasensitive and rapid detection of contaminants in liquids |
WO2000072896A1 (en) * | 1999-05-28 | 2000-12-07 | Minimed Inc. | Medication device with polymeric surface coating protecting against protein adhesion |
DE60001457T2 (en) * | 1999-06-11 | 2003-09-11 | Bausch & Lomb | LENS MOLDING TOOLS WITH PROTECTIVE LAYER FOR THE PRODUCTION OF CONTACT LENSES AND INTRAOCULAR LENSES |
US7232433B1 (en) * | 1999-09-22 | 2007-06-19 | Siemens Medical Solutions Usa, Inc. | Medical diagnostic ultrasound catheter with dielectric isolation |
US6579539B2 (en) | 1999-12-22 | 2003-06-17 | C. R. Bard, Inc. | Dual mode antimicrobial compositions |
DE60107461T2 (en) * | 2000-10-24 | 2005-05-12 | Bausch & Lomb Inc. | USE OF CATIONIC POLYSACCHARIDES FOR THE PREVENTION OF BACTERIAL APPLICATIONS |
WO2002085295A2 (en) * | 2001-04-20 | 2002-10-31 | The University Of Iowa Research Foundation | Methods and compositions for the modulation of biofilm formation |
US7402318B2 (en) * | 2001-11-14 | 2008-07-22 | Novartis Ag | Medical devices having antimicrobial coatings thereon |
US8133501B2 (en) | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US7993390B2 (en) * | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8685427B2 (en) * | 2002-07-31 | 2014-04-01 | Boston Scientific Scimed, Inc. | Controlled drug delivery |
US20070227907A1 (en) * | 2006-04-04 | 2007-10-04 | Rajiv Shah | Methods and materials for controlling the electrochemistry of analyte sensors |
US9492111B2 (en) * | 2002-04-22 | 2016-11-15 | Medtronic Minimed, Inc. | Methods and materials for stabilizing analyte sensors |
US7813780B2 (en) | 2005-12-13 | 2010-10-12 | Medtronic Minimed, Inc. | Biosensors and methods for making and using them |
US8920826B2 (en) * | 2002-07-31 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical imaging reference devices |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
CN1684722A (en) * | 2002-09-30 | 2005-10-19 | 博士伦公司 | Bacterial attachment reduction to biomaterials and biomedical devices |
US20040074785A1 (en) * | 2002-10-18 | 2004-04-22 | Holker James D. | Analyte sensors and methods for making them |
US20050272989A1 (en) * | 2004-06-04 | 2005-12-08 | Medtronic Minimed, Inc. | Analyte sensors and methods for making and using them |
US9237865B2 (en) * | 2002-10-18 | 2016-01-19 | Medtronic Minimed, Inc. | Analyte sensors and methods for making and using them |
US8425926B2 (en) | 2003-07-16 | 2013-04-23 | Yongxing Qiu | Antimicrobial medical devices |
US7192776B2 (en) * | 2004-01-28 | 2007-03-20 | James Matthew Stephens | Synthetic urine and method of manufacturing same |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
WO2007127419A2 (en) * | 2006-04-28 | 2007-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | System and method to counter material deposition on devices in the urinary tract |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
EP2084234A2 (en) * | 2006-11-08 | 2009-08-05 | Massachusetts Institute of Technology | Polymeric coatings that inactivate viruses and bacteria |
EP2109784B2 (en) | 2007-01-31 | 2016-10-05 | Novartis AG | Antimicrobial medical devices including silver nanoparticles |
CA2678598C (en) * | 2007-02-26 | 2015-02-03 | Novartis Ag | Method for imparting hydrogel contact lenses with desired properties |
US20080228193A1 (en) * | 2007-03-09 | 2008-09-18 | Anthem Orthopaedics Llc | Implantable medicament delivery device and delivery tool and method for use therewith |
TW200901890A (en) * | 2007-04-03 | 2009-01-16 | Sure Internat Ventures B V | New compostions and methods for cell killing |
EP2192923A2 (en) * | 2007-08-27 | 2010-06-09 | Massachusetts Institute of Technology | Bi-functional polymer-attached inhibitors of influenza virus |
US8148156B1 (en) | 2009-11-12 | 2012-04-03 | Brady Alfred Daniel | Synthetic urine and method for manufacturing synthetic urine |
US8660628B2 (en) * | 2009-12-21 | 2014-02-25 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
CN103073693B (en) * | 2013-02-22 | 2014-12-03 | 华南师范大学 | Waterborne polyurethane and preparation method thereof |
US9128105B2 (en) | 2013-05-06 | 2015-09-08 | Spectrum Laboratories, Llc | Urea-based synthetic urine and method of manufacturing same |
EP3484535B1 (en) | 2016-07-14 | 2022-01-19 | Hollister Incorporated | Hygienic medical devices having hydrophilic coating and methods of forming the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5306798A (en) * | 1991-10-21 | 1994-04-26 | Basf Aktiengesellschaft | Transparent, autoclavable, non-cytotoxic, essentially compact polyurethane embedding compositions, the preparation thereof and the use thereof, especially for articles used in medicine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946449A (en) * | 1986-12-18 | 1990-08-07 | Davis Jr Richard C | Indwelling urethral catheter system and method |
-
1993
- 1993-04-16 US US08/048,489 patent/US5328954A/en not_active Expired - Lifetime
-
1994
- 1994-04-14 WO PCT/US1994/004107 patent/WO1994024181A1/en active Application Filing
- 1994-04-14 AU AU67044/94A patent/AU6704494A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5306798A (en) * | 1991-10-21 | 1994-04-26 | Basf Aktiengesellschaft | Transparent, autoclavable, non-cytotoxic, essentially compact polyurethane embedding compositions, the preparation thereof and the use thereof, especially for articles used in medicine |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008063206A1 (en) * | 2008-12-29 | 2010-07-01 | Urotech Gmbh | Method for testing different materials on its applicability for the use in products that are to be processed in areas containing a fluid, in urological implant, comprises holding the materials to be tested in the form of longitudinal rods |
Also Published As
Publication number | Publication date |
---|---|
AU6704494A (en) | 1994-11-08 |
US5328954A (en) | 1994-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5328954A (en) | Encrusting and bacterial resistant coatings for medical applications | |
EP0980402B1 (en) | Encrustation and bacterial resistant coatings for medical applications | |
AU664263B2 (en) | Antibacterial coated medical implants | |
AU673400B2 (en) | M-EDTA pharmaceutical preparations and uses thereof | |
US5554147A (en) | Compositions and devices for controlled release of active ingredients | |
EP0615458B1 (en) | Method of reducing medical device related infections | |
US4950256A (en) | Non-thrombogenic intravascular time release catheter | |
Brisbois et al. | Improved hemocompatibility of multilumen catheters via nitric oxide (NO) release from S-nitroso-N-acetylpenicillamine (SNAP) composite filled lumen | |
AU611030B2 (en) | Non-thrombogenic intravascular time release catheter | |
JPH01230368A (en) | Medical tool and its production | |
EP2167564A1 (en) | Antimicrobial polyurethane resins and products made therefrom | |
US7597903B2 (en) | Method and composition for producing catheters with antibacterial property | |
CN109789244B (en) | Polypeptide and hyaluronic acid coating | |
WO2002064127A1 (en) | Methods and clinical devices for the inhibition or prevention of mammalian cell growth | |
AU2002233502A1 (en) | Methods and clinical devices for the inhibition or prevention of mammalian cell growth | |
JP2989888B2 (en) | External use medical substance and method of using the same | |
Awonusi et al. | In vitro and in vivo studies on bacteria and encrustation resistance of heparin/poly-L-lysine-Cu nanoparticles coating mediated by PDA for ureteral stent application | |
Gorman et al. | Biofilm complications of urinary tract devices | |
JP2010047764A (en) | Biocompatible polymer | |
WO1993006881A1 (en) | Therapeutic agent in hydrophilic matrix | |
US8821906B2 (en) | Biocompatible polymer | |
Gilmore et al. | Antimicrobial devices | |
CN115317674B (en) | Antibacterial drug-loaded material, preparation method thereof and application thereof in preparing catheter | |
Nix | Long Term Inhibition of Biofilm Formation on Urinary Catheters Utilizing Thin Film Coatings | |
Wo et al. | Improving the hemocompatibility of catheters via NO release/generation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |